Abstract: Methods, systems and apparatuses may provide for technology that determines the size of a graphics primitive, renders pixels associated with the graphics primitive on a per tile basis if the size exceeds a threshold, and renders the pixels associated with the graphics primitive in a mesh order if the size does not exceed the threshold. In one example, the technology discards state data associated with the graphics primitive in response to a completion of rendering the pixels associated with the graphics primitive in the mesh order.

Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Abstract: The invention relates to a plenoptic ocular device intended to be coupled in an ocular port of an optical instrument configured to generate a real image of a sample on a focal plane situated in a region close to said ocular port, said plenoptic ocular device being configured to capture said real image, generate a set of elemental images and send them to recording means with spatial discretisation which in turn comprises communication means configured to transmit the set of elemental images to external image processing means.

Abstract: Methods, systems and apparatuses may provide for technology that determines that a state of a plurality of primitives is associated with out-of-order execution. The plurality of primitives is associated with a raster order. The technology reorders the plurality of primitives from a raster order, and distributes one or more of pixel processing operations or rasterization operations associated with the plurality of primitives to load balance across one or more of a plurality of execution units of a graphics processor or a graphics pipeline of the graphics processor.

Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: Bovine milk-isolated powdered exosomes comprise intact exosomes. Nutritional compositions comprise protein, carbohydrate, and/or fat, and exosomes isolated from bovine milk. A method of preparing powdered exosomes comprises centrifuging bovine milk to form a lipid fraction top layer, a whey fraction middle layer, and a first pellet of cells and debris, separating the whey fraction and centrifuging the separated whey fraction to remove additional fat, casein aggregates and debris and form a substantially clear whey fraction, microfiltering the substantially clear whey fraction to remove residual debris, centrifuging the microfiltered whey fraction to obtain a pellet containing exosomes, incubating the exosome-containing pellet in aqueous medium to dissolve the pellet without disrupting exosome membranes to provide an exosome suspension, and drying the suspension to obtain the powdered exosomes.

Abstract: Methods, systems and apparatuses may provide for technology that selects a location of a pixel block based on a location of a graphics polygon, wherein the pixel block contains the graphics polygon. The technology may also convert the graphics polygon into a pixel-based representation within the pixel block during a single transaction.

Abstract: The present invention relates to compounds of formula I: in which m, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a and R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: Method of making foamed gypsum slurry having 15 to 90 volume percent gas bubbles including: passing first slurry including water and on dry basis 50 to 98 wt. % calcium sulfate hemihydrate, 1 to 50 wt. % calcium carbonate, and 0.1 to 10 wt. % cellulose thickener via a first hose to a Wye connector conduit first inlet opening at Rate C and passing alum solution via a second hose to a second inlet opening of the conduit at Rate D to create combined mixed stream passing from the conduit to a static mixer for mixing for Time 3 to activate at least a portion of the calcium carbonate and alum to generate CO2 and create the foamed gypsum slurry; transferring the slurry from the mixer to a cavity between two wall boards via a third hose. Allowing the slurry in the cavity to expand, harden and dry.

Abstract: A method for network function discovery in a communication network is provided. The method includes receiving a discovery request from a first network function NF to request one or more NF instance of a first group type for a first subscriber. The discovery request may include a first group type identifier of the first group type. The method may further include determining one or more group identifier for one or more groups of NF instances managing the first subscriber. The one or more groups of NF instances are of the first group type and one or more other group types. The method may further include sending a discovery response to the first network function, including the one or more group identifiers and addressing information to reach the one or more groups of NF instances.

Abstract: The present invention relates to compounds of formula I: in which m, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a and R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: Holster, support and anchorage quick release system for guns that comprises left and right assembly parts configured to guide the gun when holstered, a trigger guard ratchet, a release button and a locking mechanism, wherein the left and right assembly parts configure a holster that is laterally opened where, once the gun is holstered, the muzzle and the full length of the barrel remain leaning outwards, the holstering of the gun activates the ratchet when yielding under the insertion of the trigger guard, locking the gun in the holster and the release of the gun is produced by the actuation on the locking mechanism and the release button, so that the drawing of the gun is performed perpendicularly to the barrel, allowing to aim from the very first instant of the release of the gun, avoiding unneeded movements and providing a shooter with more time.

Abstract: In some aspects, an apparatus includes a transformer including a first inductor, a second inductor, and a third inductor. The apparatus also includes a power amplifier coupled to the first inductor, a first antenna coupled to a first terminal of the second inductor, a second antenna coupled to a second terminal of the second inductor, a first switch coupled between the first terminal of the second inductor and a ground, a second switch coupled between the second terminal of the second inductor and the ground, and a low-noise amplifier coupled to the third inductor.

Abstract: In some aspects, an apparatus includes a transformer including a first inductor, a second inductor, and a third inductor. The apparatus also includes a power amplifier coupled to the first inductor, a first antenna coupled to a first terminal of the second inductor, a second antenna coupled to a second terminal of the second inductor, a first switch coupled between the first terminal of the second inductor and a ground, a second switch coupled between the second terminal of the second inductor and the ground, and a low-noise amplifier coupled to the third inductor.

Abstract: Methods, systems and apparatuses may provide for technology that determines the size of a graphics primitive, renders pixels associated with the graphics primitive on a per tile basis if the size exceeds a threshold, and renders the pixels associated with the graphics primitive in a mesh order if the size does not exceed the threshold. In one example, the technology discards state data associated with the graphics primitive in response to a completion of rendering the pixels associated with the graphics primitive in the mesh order.

Abstract: A method of preparing a polycarbonate composition, including: melt polymerizing in a polymerization unit a dihydroxy compound with a diaryl carbonate and removing a stream of color inducing species containing an isopropenyl phenyl-containing group from the polymerization unit, to form a polycarbonate composition, wherein the polycarbonate has a color inducing species containing an isopropenyl phenyl-containing group level below 170 ppm is provided.

Abstract: The invention provided methods in vitro for diagnosis and/or prognosis of a clinical outcome in a subject with a telomere-associated disease comprising determining specific telomere associated variables (TAVs) of a test sample cell from the subject, wherein the value of the TAVs obtained for the test sample compared to a control sample is indicative of the telomerase-associated disease and/or the clinical outcome of the subject.

Abstract: A method of promoting healthy catch-up growth in a moderately malnourished individual is provided. The method includes administering to the moderately malnourished individual a nutritional composition that contains a carbohydrate blend, wherein the carbohydrate blend comprises a source of at least one carbohydrate that provides rapidly available glucose, a source of at least one carbohydrate that provides slowly available glucose, and a source of at least one non-digestible carbohydrate or resistant starch.

Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

Abstract: The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.